Robert Fruscio
Robert Fruscio is an expert in Gynecology at University of Milan (Italy). As of October 2026, ScienceLeadR ranks Robert Fruscio in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Gonadal Disorders. Robert Fruscio has authored 419 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 2 of them ongoing. SLR score: 988 (community average: 125). How the SLR is computed.
LeadR Profile
Gynecology
Subspecialties: Oncology - Obstetrics - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 419
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Editorial: Gynecological cancer prevention in women with inherited genetic risk. PMID 42827621 — genetic testing, genetic predisposition to disease, neoplasms | Front Oncol | 2026 | 0 |
| Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers. PMID 42776544 — surgical procedures, operative, ovary, neoplasms, ovarian neoplasms, salpingo-oophorectomy, ovariectomy | JAMA Surg | 2026 | 0 |
| Oncologic safety of sentinel lymph node-based nodal de-escalation in apparent uterine-confined endometrial cancer: a multicenter international cohort study. PMID 42755952 — safety, lymph nodes, lymph node excision, neoplasms, multiple chronic conditions, cohort studies, sentinel lymph node, lymph, endometrial neoplasms | Front Oncol | 2026 | 0 |
| International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study. PMID 42323120 — salpingectomy, hysterectomy, ovary, neoplasms, obstetrics, ovarian neoplasms, gynecology, genes, brca1, salpingo-oophorectomy, ovariectomy, endometrial neoplasms | Am J Obstet Gynecol | 2026 | 0 |
| Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. PMID 42745296 — poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, ovary, neoplasms, poly adenosine diphosphate ribose, dna topoisomerases, type i, ovarian neoplasms, topoisomerase i inhibitors | Exp Hematol Oncol | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| BRCA Mutation Carriers Platform a Multicenter Study NCT07253051 — genes, neoplasms, genes, brca2, genes, brca1, mutation, female, women | N/A | Recruiting | 2025 |
| Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real world Scenario NCT06836219 — recombination, genetic, homologous recombination, ovary, neoplasms, ovarian neoplasms, therapeutics, carcinoma, ovarian epithelial, carcinoma | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map